动物造模,发性炎性肠病大鼠 z-bio 2021-03-05 554

　　Objective: To investigate the therapeutic effect of anti-complement 5a receptor (C5aR) antibody combined with allicin on inflammatory bowel disease (IBD) in rats.

　　Method: IBD male rats induced by 802,4,6-trinitrobenzenesulfonic acid (TNBS) were divided into four groups: model control group, anti-C5aR antibody treatment group, alixilin treatment group and anti-C5aR antibody treatment group. Are divided randomly. C5aR antibody combined with allicin treatment group; another 20 male rats served as normal control group. 14 days before and after forced feeding, the weight change and survival rate of the rats were counted to detect the levels of interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) in the rat serum, and measures were usually taken. Colon tissue analysis. Observation and pathological scoring.

　　Result: The body weight and survival rate of rats in the anti-C5aR antibody combined with allicin treatment group were higher than those in other treatment groups, and the expression levels of inflammatory factors II-6 and TNF-α in their serum were higher. There is a clear trend of regression; the histopathological score of the colon also shows that the efficacy of the combined treatment group is significantly better than that of the other treatment groups (P\u003c0.05).

　　Conclusion: The combination of anti-C5aR antibody and allicin is an effective method to treat TNBS-induced IBD, and its therapeutic effect is better than using anti-C5aR antibody or allicin alone.